The company’s last traded volume of 29.21 million shares was more it’s an average volume of 26.7 million shares. Premier Asset Managment LLC now owns 48,121 shares of the biopharmaceutical company’s stock valued at $1,629,000 after buying an additional 1,475 shares in the last quarter. Finally, Cullen Frost Bankers Inc. raised its stake in Pfizer by 0.8% in the third quarter. The Salem Investment Counselors Inc holds 333,440 shares with $10.83 million value, down from 381,202 last quarter. Nationwide Fund Advisors raised its stake in Pfizer by 3.9% in the third quarter. First Hawaiian Bank boosted its stake in shares of Pfizer by 0.3% in the third quarter. State Street Corp now owns 320,794,199 shares of the biopharmaceutical company’s stock worth $10,419,393,000 after buying an additional 10,838,463 shares during the last quarter. Stratos Wealth Partners LTD. boosted its stake in Pfizer by 6.9% in the third quarter. Bank of The West now owns 157,475 shares of the biopharmaceutical company’s stock valued at $5,334,000 after buying an additional 34,415 shares during the last quarter.
Pfizer Inc. (PFE) is an interesting player in the Healthcare space, with a focus on Drug Manufacturers – Major.
Pfizer Inc. (PFE) stock price distance from twenty day simple moving average slumped at -1.09% while its distance from fifty day simple moving average declined -1.97% along with 1.02% above distance from two hundred simple moving averages.
The stock’s price switched up 6.62% 20-Days Simple Moving Average, added 8.49% from 50-Days Simple Moving Average and rose 39.58% from 200 Days Simple Moving Average. Pfizer, Inc. has a 52-week low of 29.83 and a 52-week high of 37.39. The stock has a market capitalization of $196.47 billion, a price-to-earnings ratio of 27.79 and a beta of 0.94.
Pfizer Inc. (PFE) stock price tumbled -0.21% to finalize at $33.38 throughout previous buying and selling session. The biopharmaceutical company reported $0.69 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.67 by $0.02. The firm had revenue of $12.78 billion for the quarter, compared to analysts’ expectations of $13.09 billion. Pfizer had a net margin of 13.50% and a return on equity of 23.18%.
Over the last 5 years, Pilgrim’s Pride Corporation has averaged a 22.70% YoY EPS growth rate and a 1.00% revenue growth rate. They expect $0.65 EPS, up 1.56% or $0.01 from last year’s $0.64 per share. Equities research analysts forecast that Pfizer Inc. will post $2.55 EPS for the current year.
The business also recently declared a quarterly dividend, which will be paid on Thursday, June 1st. The average true range of the stock is observed at 0.71 and the relative strength index of the stock is recorded at 65.74. The ex-dividend date of this dividend is Wednesday, May 10th. This represents a $1.28 annualized dividend and a yield of 3.83%. Pfizer’s payout ratio is now 110.35%. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Pfizer Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.
TRADEMARK VIOLATION NOTICE: This piece of content was first reported by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this report on another publication, it was illegally copied and republished in violation of USA & global copyright law. The correct version of this news story can be viewed at https://www.themarketsdaily.com/2017/05/12/cypress-wealth-advisors-llc-lowers-position-in-pfizer-inc-pfe-updated-updated.html.
Stock market analysts and brokers have recently amended their target prices on shares of Pfizer, Inc. Barclays PLC set a $38.00 price objective on shares of Pfizer and gave the company a “buy” rating in a research note on Thursday, March 16th. Piper Jaffray Companies set a $53.00 price objective on Pfizer and gave the stock a “buy” rating in a report on Saturday, January 21st. Goldman Sachs Group Inc set a $36.00 target price on shares of Pfizer and gave the stock a “neutral” rating in a research report on Wednesday, January 18th. (NYSE:PFE) stock a Strong Buy, 0 rate the stocks of the company a Buy, 8 rate Hold, 0 rate Sell and 0 recommend a Strong Sell. (NYSE:PFE)’s price target was revised on 05/05/17 and according to 19 analysts stock’s price will reach at $37.89 during 52 weeks with standard deviation of 5.44.
In other news, insider Charles H. Hill sold 36,000 shares of Pfizer stock in a transaction that occurred on Thursday, March 9th. The stock was sold at an average price of $34.07, for a total value of $1,226,520.00. Following the sale, the insider now owns 64,719 shares in the company, valued at $2,233,452.69. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Rady A. Johnson sold 4,500 shares of the business’s stock in a transaction on Friday, March 10th. The lowest 12-month price target for the shares is $21.00, which would be decrease of about -15% of its current value. Following the completion of the transaction, the insider now owns 54,963 shares in the company, valued at $1,879,184.97. The disclosure for this sale can be found here. 20,000 shares were sold by LANKLER DOUGLAS M, worth $693,200 on Thursday, March 2. Perhaps, that suggests something about why 0.23% of the outstanding share supply is held by institutional investors.
